Mobina Gheibi

Mobina Gheibi

Auto-generated profile, based on publicly available information

Mobina Gheibi

Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
PKPouria Kiani
Pouria Kiani
EKElaheh Sadat Khodadadi
Elaheh Sadat Khodadadi
ANAli Nikdasti
Ali Nikdasti
SYSahar Yarahmadi
Sahar Yarahmadi
MGMobina Gheibi
Mobina Gheibi
MPMorteza Pourfarzam
Morteza Pourfarzam

22 May 2025 in Clinics
Verified
Journal Article
Open access
EGErfan Ghadirzadeh
Erfan Ghadirzadeh
MMMahmood Moosazadeh
Mahmood Moosazadeh
KSKiarash Shakeriastani
Kiarash Shakeriastani
MZMaryam Zarrinkamar
Maryam Zarrinkamar
MGMobina Gheibi
Mobina Gheibi
MGMojgan Geran
Mojgan Geran
The existing literature presents conflicting findings regarding the relationship between Age At Menarche (AAM) and depression. Thus, to address this gap, this systematic review and meta-analysis aimed to evaluate current evidence to clarify the association between AAM and depression. Medline (PubMed), Scopus, Embase, Web of Science, and Google Scholar were searched from 2000 until June 2024 to include cross-sectional, case-control, and cohort studies. The quality of the evidence was assessed using the Newcastle-Ottawa Scale (NOS) instrument. The odds ratio (OR) of depression and its 95 % Confidence Interval (95 % CI) were calculated using the random effects model and inverse variance method. The protocol is registered in PROSPERO, number CRD42024551838. From a total of 2175 search records, 13 studies were included comprising 434,838 participants with NOS scores ranging from 7 to 9. The present findings showed that early menarche is associated with significantly higher odds of depression compared to both normative AAM (OR = 1.36, 95 % CI: 1.20‒1.53) and late AAM (OR = 1.52, 95 % CI 1.22‒1.90). Also, females with later menarche had lower odds of depression compared to females with normal AAM (OR = 0.91, 95 % CI 0.76‒1.09); however, this association was not statistically significant. The present findings demonstrated that early menarche is associated with elevated odds of depression compared to females of both normative AAM and late AAM.

16 March 2025 in Inhalation Toxicology
Verified
Journal Article
Closed access
EGErfan Ghadirzadeh
Erfan Ghadirzadeh
MMMahmood Moosazadeh
Mahmood Moosazadeh
MKMotahareh Kheradmand
Motahareh Kheradmand
MBMasoumeh Bagheri-Nesami
Masoumeh Bagheri-Nesami
SGSajad Ghafari-Cherati
Sajad Ghafari-Cherati
AHAmirsaeed Hosseini
Amirsaeed Hosseini
Cigarette smoking stands as a prominent contributor to global mortality rates, and its impact spans both immediate and long-term effects on hematological parameters; however, in addition to controversial results in previous studies, its effect on novel inflammatory indices has yet to be thoroughly investigated. Thus, this study aims to assess the impact of various smoking profiles on total white blood cell (WBC) count, WBC differentials, and novel hematologic-inflammatory indices among males. This cross-sectional study was conducted on 4039 male adults from the enrollment phase data of the TABARI cohort population in Iran. WBC, absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), platelet-to-HDL ratio (PHR), RDW-to-platelet ratio (RPR), lymphocyte-to-HDL ratio (LHR), monocyte-to-HDL ratio (MHR), and neutrophil-to-HDL ratio (NHR) were compared between smokers and nonsmokers and also within smokers with different smoking intensities (pack/year). Comparisons were made by Chi-square test and one-way ANOVA, and further done using multivariate linear regression after adjustment for confounders. WBC, ANC, ALC, AMC, LMR, PLR, PHR, LHR, MHR, and NHR were significantly higher in smokers compared to nonsmokers in a dose-dependent manner (p < 0.05). The multivariate linear regression showed that among smokers, WBC was 25.3% higher, ANC and ALC were 19.7% higher, and AMC was 12.2% higher compared to nonsmokers (all p < 0.001). Our results demonstrated that WBC, ANC, ALC, AMC, PHR, LHR, MHR, and NHR exhibit significant dose-dependent elevations in smokers.

18 July 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
HMHossein Mehravaran
Hossein Mehravaran
ABAdeleh Bahar
Adeleh Bahar
FHFatemeh Hajimohammadi
Fatemeh Hajimohammadi
ZKZahra Kashi
Zahra Kashi
MAMasoud Aliyali
Masoud Aliyali
EGErfan Ghadirzadeh
Erfan Ghadirzadeh
Introduction: Metabolic syndrome (MetS) could be associated with worsened asthma control and more severe and frequent asthma attacks. Metformin has been suggested as a potential treatment for MetS, which could decrease airway reactivity and lead to improved asthma control and reduced emergency department (ED) visits. However, the existing data have predominantly focused on diabetic patients only. Thus, in the present study, we aimed to investigate the effects of metformin in patients with concurrent asthma and MetS. Methods: This trial was conducted on two groups of patients (55 in each group) with concurrent asthma and MetS, each receiving either metformin hydrochloride or an identical placebo. Patients were followed up after 3 months and assessed regarding clinical outcomes, asthma control tests (ACTs), pulmonary function test parameters, C-reactive protein (CRP) levels, frequency of asthma attacks, ED visits, and hospitalization rate. Results: The metformin group showed statistically significant improvements in indices regarding ACT score, O2 saturation, anthropometric indices, blood sugar control, CRP, and lipid profile compared to the placebo group (all P < 0.05). Additionally, the metformin group showed significantly higher forced expiratory volume in 1 s (FEV1) (P = 0.014, and effect size = 5.6%) and forced vital capacity (FVC) (P = 0.001, and effect size = 9.2%) in the multivariate analysis after controlling for the confounding effects of baseline parameters and sex. Although the metformin group demonstrated a trend toward a reduction in severe asthma attacks, ED visits, or hospitalization rates, the effects were not statistically significant (P > 0.05). Conclusion: Our findings demonstrate that metformin administration in patients with concurrent asthma and MetS could lead to substantial enhancements in ACT score, FEV1, and FVC.

12 November 2025 in Behavioral and Brain Functions
Verified
Journal Article
Open access
PDF file
EGErfan Ghadirzadeh
Erfan Ghadirzadeh
MGMobina Gheibi
Mobina Gheibi
AKAli Siahposht Khachaki
Ali Siahposht Khachaki
EHEhsan Vahdati Helan
Ehsan Vahdati Helan
MFMohammad Farvardin
Mohammad Farvardin
AAAli Abdolkarimi
Ali Abdolkarimi
Background: Morphine addiction is a growing problem with severe consequences. Interestingly, Insulin-like Growth Factor-1 (IGF-1), a hormone with the ability to modulate neural pathways and exert neuroprotective and regenerative properties, could emerge as a potential treatment. However, to the best of our knowledge, the role of IGF-1 in the extinction and reinstatement phases of morphine induced conditioned place preference (CPP) remains unexplored. Thus, this study aimed to investigate the behavioral and biochemical effects of intracerebroventricular (ICV) IGF-1 administration on extinction and reinstatement after morphine induced CPP and c-Fos expression in nucleus accumbens (NAc). Methods: Rats were conditioned with morphine (5 mg/kg, subcutaneously). The study examined alterations in CPP scores after administering varying multiple doses of IGF-1 (5, 10, and 20 µg) daily during the extinction and reinstatement phases of CPP, or single 20 µg dose administration prior to the extinction or prior to the reinstatement phase. Following these procedures, c-Fos levels in the NAc were quantified using the ELISA method. Results: The findings revealed that daily administration of IGF-1 at doses of 5, 10, and 20 µg resulted in a dose-dependent reduction in conditioning scores and shorter extinction period. Importantly, only the 20 µg attenuated morphine reinstatement significantly. Additionally, c-Fos levels, which increased following morphine exposure, were markedly reduced by IGF-1 administration across all phases. Conclusion: This study demonstrates that IGF-1 administration could facilitates the extinction and attenuate the reinstatement of morphine-induced CPP, highlighting its potential as a therapeutic strategy in opioid addiction.

1 March 2025 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
SNSomayeh Nazari
Somayeh Nazari
MGMobina Gheibi
Mobina Gheibi
PSPouria Salehi Sangani
Pouria Salehi Sangani
FFFarzaneh Felehkari
Farzaneh Felehkari
FGFarnam Gohardehi
Farnam Gohardehi
RRRaheleh Rafaiee
Raheleh Rafaiee
Introduction: Opioid dependence significantly disrupts cognitive activities such as learning and memory, which may be the reason for a return to drug use. Morphine (MOR) can increase oxidative damage in the brain. We aim to investigate the effect of coenzyme Q10 (CoQ10) on cognitive impairment, cue-related reinstatement, and expression of brain-derived ...